• AI
  • Molecular Imaging
  • CT
  • X-Ray
  • Ultrasound
  • MRI
  • Facility Management
  • Mammography

Hitachi acquires stake in AccSys

Article

In a bid to expand its market share in the radiotherapy market, Hitachi has acquired 80% of AccSys Technology, a developer of ion linear accelerator (linac) technology. The acquisition allows Hitachi to increase its presence in the emerging market for

In a bid to expand its market share in the radiotherapy market, Hitachi has acquired 80% of AccSys Technology, a developer of ion linear accelerator (linac) technology. The acquisition allows Hitachi to increase its presence in the emerging market for proton-beam therapy, a localized form of radiation therapy in which a proton beam is directed at a tumor deep in the body. Proton beams appear to cause fewer side effects compared with conventional electron-beam and x-ray therapy. Hitachi developed its own proton-beam therapy system, called Probeat, which includes a linac injector supplied by AccSys.

Related Videos
Does Initial CCTA Provide the Best Assessment of Stable Chest Pain?
Making the Case for Intravascular Ultrasound Use in Peripheral Vascular Interventions
Can Diffusion Microstructural Imaging Provide Insights into Long Covid Beyond Conventional MRI?
Assessing the Impact of Radiology Workforce Shortages in Rural Communities
Emerging MRI and PET Research Reveals Link Between Visceral Abdominal Fat and Early Signs of Alzheimer’s Disease
Reimbursement Challenges in Radiology: An Interview with Richard Heller, MD
Nina Kottler, MD, MS
The Executive Order on AI: Promising Development for Radiology or ‘HIPAA for AI’?
Related Content
© 2024 MJH Life Sciences

All rights reserved.